These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7614957)

  • 1. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia.
    Bohte R; van't Wout JW; Lobatto S; Blussé van Oud Alblas A; Boekhout M; Nauta EH; Hermans J; van den Broek PJ
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):182-7. PubMed ID: 7614957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
    Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
    Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
    Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
    J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia.
    Gaillat J; Bru JP; Sedallian A
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):639-44. PubMed ID: 7813493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.
    Vergis EN; Indorf A; File TM; Phillips J; Bates J; Tan J; Sarosi GA; Grayston JT; Summersgill J; YU VL
    Arch Intern Med; 2000 May; 160(9):1294-300. PubMed ID: 10809032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is azithromycin monotherapy as efficacious as cefuroxime plus erythromycin for the treatment of community-acquired pneumonia in hospitalized patients?
    See S
    J Fam Pract; 2000 Oct; 49(10):883-4. PubMed ID: 11052155
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia.
    Paladino JA; Gudgel LD; Forrest A; Niederman MS
    Chest; 2002 Oct; 122(4):1271-9. PubMed ID: 12377852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia.
    Rizzato G; Montemurro L; Fraioli P; Montanari G; Fanti D; Pozzoli R; Magliano E
    Eur Respir J; 1995 Mar; 8(3):398-402. PubMed ID: 7789484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report.
    Uzun O; Hayran M; Akova M; Gür D; Akalin HE
    J Chemother; 1994 Feb; 6(1):53-7. PubMed ID: 8071680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
    Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etiology and treatment of community-acquired pneumonia in ambulatory children.
    Wubbel L; Muniz L; Ahmed A; Trujillo M; Carubelli C; McCoig C; Abramo T; Leinonen M; McCracken GH
    Pediatr Infect Dis J; 1999 Feb; 18(2):98-104. PubMed ID: 10048679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections.
    Roord JJ; Wolf BH; Gossens MM; Kimpen JL
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2765-8. PubMed ID: 9124837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.
    Plouffe J; Schwartz DB; Kolokathis A; Sherman BW; Arnow PM; Gezon JA; Suh B; Anzuetto A; Greenberg RN; Niederman M; Paladino JA; Ramirez JA; Inverso J; Knirsch CA
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1796-802. PubMed ID: 10858333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
    Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.
    Harris JA; Kolokathis A; Campbell M; Cassell GH; Hammerschlag MR
    Pediatr Infect Dis J; 1998 Oct; 17(10):865-71. PubMed ID: 9802626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
    Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
    J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
    Rahav G; Fidel J; Gibor Y; Shapiro M
    Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila.
    Tan JS; File TM; DiPersio JR; DiPersio LP; Hamor R; Saravolatz LD; Stout JE
    Clin Infect Dis; 2001 Jun; 32(11):1562-6. PubMed ID: 11340527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.